+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Increase in Renal and Urinary Low and High Molecular Weight Kininogens during Chromate-Induced Acute Renal Failure in the Rat: Evidence for Renal Kininogen Production

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In the present study, we investigated the plasma, urinary and intrarenal concentrations of low and high molecular weight kininogens during sodium chromate (25 mg/kg body weight)-induced acute renal failure (ARF) in the rat. Urinary kininogen underwent a transient increase with a maximum on day 7 (78 ± 22 versus 4.2 ± 1.6 ng bradykinin/mg creatinine) whereas plasma kininogen did not and glomerular filtration rate decreased (92 ± 8 versus 895 ± 70 μl/min). The tissue level of kininogen was enhanced both in the cortex (1,319 ± 123 versus 86 ± 8 pg bradykinin Eq/mg protein) and in the medulla (1,673 ± 138 versus 44 ± 9 pg bradykinin Eq/mg protein) but more in the medulla (36 ± 4- versus 15 ± 3-fold). As plasma kininogen level was unchanged and glomerular filtration rate decreased, the increase in both renal concentration and urinary excretion of kininogen probably reflects stimulated renal production of kininogen in this model of ARF. Whether the evoked renal production of kininogen results from a local inflammatory response only or may subserve another physiological purpose remains to be elucidated.

          Related collections

          Author and article information

          S. Karger AG
          12 December 2008
          : 65
          : 4
          : 612-618
          aINSERM U133, Centre de Recherche Louis Bugnard, Faculté de Médecine Rangueil, Toulouse, France; bFaculté de Pharmacie, Université de Montréal, Canada cLaboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Ribeirao Preto USP, Brazil
          187573 Nephron 1993;65:612–618
          © 1993 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper

          Cardiovascular Medicine, Nephrology

          Kallikrein, Renal failure, Kininogen, Chromate


          Comment on this article